Acura Pharmaceuticals, Inc. Stock Price - ACUR

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Acura Pharmaceuticals, Inc. ACUR Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 0.201 0.00 0.00 0.00 0.201 16:10:45
Bid Price Ask Price Spread Spread % News
0.02 0.24 0.22 91.67% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Acura Pharmaceuticals, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 4.28M 21.30M $ -5.68M - -0.75 7.39M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
11.62k $ - 0.00% - -

more financials information »

Acura Pharmaceuticals, Inc. News

Latest ACUR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACUR Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.2550.2690.20.21815k-0.054-21.18%
1 Month0.140.270.13010.22195k0.06143.57%
3 Months0.180.2830.13010.23186k0.02111.67%
6 Months0.17250.290.13010.20597k0.028516.52%
1 Year0.35990.370.06010.198811k-0.1589-44.15%
3 Years0.550.87020.06010.427216k-0.349-63.45%
5 Years0.550.87020.06010.427216k-0.349-63.45%

Acura Pharmaceuticals, Inc. Description

We are an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx Technology is being developed to minimize the risk of opioid overdose, our Aversion Technology is intended to address methods of abuse associated with opioid analgesics while our Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. Our Limitx Technology is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. On June 28, 2019, we entered into License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC, a Kentucky limited liability company, a special purpose company representing a consortium of investors that will finance Acura's operations and completion of development of LTX-03.

Your Recent History
Acura Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.